{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:59:09Z","timestamp":1783130349136,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s13277-015-4031-9","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T02:17:29Z","timestamp":1443493049000},"page":"3009-3016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients\u2014results from the OVCAD study"],"prefix":"10.1007","volume":"37","author":[{"given":"Mani","family":"Nassir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Luketina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Siepmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Cacsire","family":"Castillo-Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Nieuwenhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"Woelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Ioana","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"issue":"5","key":"4031_CR1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13277-012-0381-8","volume":"33","author":"T Granato","year":"2012","unstructured":"Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012;33(5):1335\u20139.","journal-title":"Tumour Biol"},{"issue":"6","key":"4031_CR2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","volume":"33","author":"F Plotti","year":"2012","unstructured":"Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiania P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33(6):2117\u201323.","journal-title":"Tumour Biol"},{"issue":"3","key":"4031_CR3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374\u201382.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"4031_CR4","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1007\/s13277-014-1836-x","volume":"35","author":"R Angioli","year":"2014","unstructured":"Angioli R, Capriglione S, Aloisi A, Guzzo F, Luvero D, Miranda A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014;35(7):7009\u201315.","journal-title":"Tumour Biol"},{"issue":"3","key":"4031_CR5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","volume":"121","author":"P Harter","year":"2011","unstructured":"Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121(3):615\u20139.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4031_CR6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","volume":"125","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u2018optimal\u2019 residual disease. Gynecol Oncol. 2012;125(2):483\u201392.","journal-title":"Gynecol Oncol"},{"issue":"31","key":"4031_CR7","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2011.35.9935","volume":"29","author":"DS Chi","year":"2011","unstructured":"Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol. 2011;29(31):4073\u20135.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4031_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00001622-200009000-00015","volume":"12","author":"RE Bristow","year":"2000","unstructured":"Bristow RE. Surgical standards in the management of ovarian cancer. Curr Opin Oncol. 2000;12(5):474\u201380.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"4031_CR9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","volume":"128","author":"EI Braicu","year":"2013","unstructured":"Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. J Gynecol Oncol. 2013;128(2):245\u201351.","journal-title":"J Gynecol Oncol"},{"key":"4031_CR10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","volume":"3","author":"M Haries","year":"2002","unstructured":"Haries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002;3:529\u201336.","journal-title":"Lancet Oncol"},{"key":"4031_CR11","doi-asserted-by":"crossref","unstructured":"Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 31(2):113\u20139.","DOI":"10.1007\/s13277-009-0015-y"},{"key":"4031_CR12","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162\u20139.","journal-title":"Cancer Res"},{"key":"4031_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","volume":"95","author":"MW McIntosh","year":"2004","unstructured":"McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95:9\u201315.","journal-title":"Gynecol Oncol"},{"key":"4031_CR14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19","author":"MT Galgano","year":"2006","unstructured":"Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847\u201353.","journal-title":"Mod Pathol"},{"issue":"9747","key":"4031_CR15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","volume":"376","author":"GJ Rustin","year":"2010","unstructured":"Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155\u201363.","journal-title":"Lancet"},{"issue":"4","key":"4031_CR16","first-page":"511","volume":"79","author":"S Grover","year":"1992","unstructured":"Grover S, Quinn MA, Weidemann P, Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol. 1992;79(4):511\u20134.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"4031_CR17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1530\/ror.0.0030086","volume":"3","author":"C Kirchhoff","year":"1998","unstructured":"Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3(2):86\u201395. Review.","journal-title":"Rev Reprod"},{"issue":"2","key":"4031_CR18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","volume":"419","author":"R Lu","year":"2012","unstructured":"Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012;419(2):274\u201380.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10\u201311","key":"4031_CR19","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","volume":"44","author":"Y Park","year":"2011","unstructured":"Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10\u201311):884\u20138.","journal-title":"Clin Biochem"},{"key":"4031_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-405211-6.00001-2","volume":"59","author":"MM Speeckaert","year":"2013","unstructured":"Speeckaert MM, Speeckaert R, Delanghe JR. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem. 2013;59:1\u201321.","journal-title":"Adv Clin Chem"},{"issue":"2","key":"4031_CR21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/IGC.0b013e31827de6b9","volume":"23","author":"R Chekerov","year":"2013","unstructured":"Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, et al. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer. 2013;23(2):268\u201375.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"4031_CR22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4031_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323.","journal-title":"Int J Gynecol Cancer"},{"issue":"Supp 2","key":"4031_CR24","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1111\/IGC.0b013e3181bf7fb8","volume":"19","author":"M Friedlander","year":"2009","unstructured":"Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Donovan OA, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory\/resistant ovarian cancer. Int J Gynecol Cancer. 2009;19(Supp 2):S44\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"4031_CR25","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3892\/or.2013.2682","volume":"30","author":"L Manganaro","year":"2013","unstructured":"Manganaro L, Michienzi S, Vinci V, Falzarano R, Saldari M, Granato T, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30(5):2481\u20137.","journal-title":"Oncol Rep"},{"issue":"8","key":"4031_CR26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/IGC.0000000000000218","volume":"24","author":"E Piovano","year":"2014","unstructured":"Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359\u201365.","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 6","key":"4031_CR27","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi24\u201332.","journal-title":"Ann Oncol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-4031-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-4031-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T22:30:04Z","timestamp":1567204204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-4031-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["4031"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-4031-9","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}